The number of millennials with early-onset Alzheimer's disease is surging, report finds

Independence Blue Cross report examines increased dementia diagnoses

The number of Americans being diagnosed with early-onset dementia and Alzheimer's disease at younger ages is surging, according to a new report from the Blue Cross Blue Shield Association.
Kyle Broad/Unsplash.com

Dementia and Alzheimer's disease traditionally have been considered a concern for older generations. But recent spikes in early onset of these conditions in Americans as young as 30 suggest a different story. 

Between 2013 and 2017, early-onset dementia and Alzheimer's diagnoses increased by 83% among commercially insured Americans aged 30 to 44, according to a report released by the health care insurer. That age group includes the oldest millennials.

Overall, early-onset diagnoses increased by 200% among commercially insured Americans between ages 30 to 64. That included a 50% jump among those 45 to 54 and by 40% for those aged 55 to 64. 

The average patient was diagnosed at age 49.

"The results of this report are concerning, especially the increase in early-onset dementia and Alzheimer's disease among younger people," Dr. Richard Snyder, chief medical officer for Independence Blue Cross, said in a statement.

"While the underlying cause is not clear, advances in technology are certainly allowing for earlier and more definitive diagnosis. Regardless, those who develop dementia or Alzheimer's at an early age will likely require caregiving, either from family members or healthcare providers. The time, cost and impact on families can be significant and can require additional support as these diseases progress."

Diagnosis rates were higher in the East, South and parts of the Midwest. Women made up 58% of the diagnoses.

Alzheimer's, the most common type of dementia, begins with mild memory loss, eventually progressing to the point where victims can no longer hold a conversation or respond to their environments. Symptoms generally occur after age 60. 

Earlier this year, researchers said a vaccine that both prevents and treats Alzheimer's could be ready for human trials within 18 months. 

In 2017, more than 37,000 commercially-insured Americans between the ages 30-64 were diagnosed with Alzheimer's, according to the report. This marked a 131% spike since 2013.

While the consequence of these numbers are wide-ranging, informal caregivers will carry much of the burden. They often struggle with depression, social isolation and financial stress.

Almost 16 million people provide more than 18 billion hours of unpaid care to a family member or friend with Alzheimer's disease in America – an estimated price tag of $221 billion.